Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Mafenide | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Mafenide | hsa00220 | Arginine biosynthesis | 1.54E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Mafenide | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Mafenide | hsa00531 | Glycosaminoglycan degradation | 8.18E-04 | 2 | P15586, P34059 | GNS, GALNS | More | | Mafenide | hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 2.92E-02 | 1 | Q9Y2C2 | UST | More | | Mafenide | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Mafenide | hsa00910 | Nitrogen metabolism | 2.93E-02 | 2 | P22748, P49448 | CA4, GLUD2 | More | | Mafenide | hsa00983 | Drug metabolism - other enzymes | 3.20E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Mafenide | hsa01522 | Endocrine resistance | 4.55E-02 | 5 | P14780, P22694, Q9UM47, P10415, Q13323 | MMP9, PRKACB, NOTCH3, BCL2, BIK | More | | Mafenide | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | Mafenide | hsa03008 | Ribosome biogenesis in eukaryotes | 2.06E-02 | 2 | Q9NYH9, Q9BVP2 | UTP6, GNL3 | More | | Mafenide | hsa03013 | RNA transport | 3.98E-02 | 9 | P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | | Mafenide | hsa04060 | Cytokine-cytokine receptor interaction | 5.39E-03 | 10 | P27930, P08476, Q13651, Q9HBE5, Q9UBD3, P47992, P01375, P09341, P18510, Q93038 | IL1R2, INHBA, IL10RA, IL21R, XCL2, XCL1, TNF, CXCL1, IL1RN, TNFRSF25 | More | | Mafenide | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.34E-02 | 5 | P09341, P47992, Q9UBD3, Q13651, P01375 | CXCL1, XCL1, XCL2, IL10RA, TNF | More | | Mafenide | hsa04064 | NF-kappa B signaling pathway | 1.59E-04 | 13 | P10415, Q13489, P51617, O00463, P01375, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q13315, P24522, P09341 | BCL2, BIRC3, IRAK1, TRAF5, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, ATM, GADD45A, CXCL1 | More | | Mafenide | hsa04071 | Sphingolipid signaling pathway | 4.62E-05 | 8 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | Mafenide | hsa04080 | Neuroactive ligand-receptor interaction | 4.72E-02 | 8 | P08311, Q15722, P21453, Q9H228, O00398, P21462, P21730, Q16581 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, C3AR1 | More | | Mafenide | hsa04140 | Autophagy - animal | 4.55E-02 | 5 | P22694, Q14643, P10415, Q9H1Y0, Q04759 | PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | | Mafenide | hsa04142 | Lysosome | 1.14E-02 | 3 | P43234, P15586, P34059 | CTSO, GNS, GALNS | More | | Mafenide | hsa04145 | Phagosome | 1.08E-02 | 8 | O75015, Q15080, P14598, Q13509, P05164, O60603, P35443, P13765 | FCGR3B, NCF4, NCF1, TUBB3, MPO, TLR2, THBS4, HLA-DOB | More | | Mafenide | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | | Mafenide | hsa04210 | Apoptosis | 9.18E-03 | 4 | P04637, P24522, P43234, P63261 | TP53, GADD45A, CTSO, ACTG1 | More | | Mafenide | hsa04340 | Hedgehog signaling pathway | 3.46E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Mafenide | hsa04610 | Complement and coagulation cascades | 1.29E-05 | 2 | P00734, P0C0L4 | F2, C4A | More | | Mafenide | hsa04612 | Antigen processing and presentation | 1.05E-03 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Mafenide | hsa04613 | Neutrophil extracellular trap formation | 1.86E-05 | 16 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, P14598, Q15080, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, NCF1, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Mafenide | hsa04621 | NOD-like receptor signaling pathway | 2.62E-02 | 11 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, DEFA4 | More | | Mafenide | hsa04640 | Hematopoietic cell lineage | 4.96E-02 | 6 | P27930, P25063, P09693, P01732, P13765, P01375 | IL1R2, CD24, CD3G, CD8A, HLA-DOB, TNF | More | | Mafenide | hsa04650 | Natural killer cell mediated cytotoxicity | 2.94E-03 | 8 | P01375, P06239, O60880, P20963, Q13241, P26718, P26717, P26715 | TNF, LCK, SH2D1A, CD247, KLRD1, KLRK1, KLRC2, KLRC1 | More | | Mafenide | hsa04657 | IL-17 signaling pathway | 2.68E-04 | 8 | O00463, Q16539, P49841, P09341, P14780, Q9UJX4, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, ANAPC5, LCN2, TNF | More | | Mafenide | hsa04658 | Th1 and Th2 cell differentiation | 8.55E-05 | 9 | Q04759, P20963, P09693, Q16539, P06239, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, LCK, STAT4, GATA3, TBX21, HLA-DOB | More | | Mafenide | hsa04659 | Th17 cell differentiation | 3.55E-03 | 8 | Q04759, P06239, P13765, Q9HBE5, Q9UL17, P23771, P09693, P20963 | PRKCQ, LCK, HLA-DOB, IL21R, TBX21, GATA3, CD3G, CD247 | More | | Mafenide | hsa04660 | T cell receptor signaling pathway | 3.16E-05 | 12 | P01375, Q9UDY8, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, MALT1, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Mafenide | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 5 | O75015, P06396, O14494, P14598, P17252 | FCGR3B, GSN, PLPP1, NCF1, PRKCA | More | | Mafenide | hsa04940 | Type I diabetes mellitus | 4.18E-02 | 3 | P10747, P13765, P01375 | CD28, HLA-DOB, TNF | More | | Mafenide | hsa04964 | Proximal tubule bicarbonate reclamation | 2.74E-03 | 3 | P22748, P00918, P49448 | CA4, CA2, GLUD2 | More | | Mafenide | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Mafenide | hsa05133 | Pertussis | 2.64E-03 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | | Mafenide | hsa05140 | Leishmaniasis | 4.75E-04 | 9 | P13612, O75015, P14598, P13765, O60603, P01375, Q16539, P51617, Q15080 | ITGA4, FCGR3B, NCF1, HLA-DOB, TLR2, TNF, MAPK14, IRAK1, NCF4 | More | | Mafenide | hsa05143 | African trypanosomiasis | 1.74E-03 | 2 | P69905, P68871 | HBA2, HBB | More | | Mafenide | hsa05144 | Malaria | 3.09E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Mafenide | hsa05146 | Amoebiasis | 1.39E-03 | 8 | P09341, P27930, P01375, O60603, P05089, P22694, P12814, P08311 | CXCL1, IL1R2, TNF, TLR2, ARG1, PRKACB, ACTN1, CTSG | More | | Mafenide | hsa05150 | Staphylococcus aureus infection | 1.65E-02 | 6 | P21730, P21462, O75015, P13765, Q16581, P49913 | C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, CAMP | More | | Mafenide | hsa05152 | Tuberculosis | 8.54E-03 | 9 | O75015, P48382, O60603, P01375, P10415, P13765, P49913, Q9UDY8, P51617 | FCGR3B, RFX5, TLR2, TNF, BCL2, HLA-DOB, CAMP, MALT1, IRAK1 | More | | Mafenide | hsa05202 | Transcriptional misregulation in cancer | 1.50E-06 | 20 | Q12778, Q15532, Q13315, P41732, P14780, P27930, P14923, Q15744, Q16548, Q13489, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P12980, P24522 | FOXO1, SS18, ATM, TSPAN7, MMP9, IL1R2, JUP, CEBPE, BCL2A1, BIRC3, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, LYL1, GADD45A | More | | Mafenide | hsa05205 | Proteoglycans in cancer | 4.43E-02 | 3 | P63261, P04637, Q06124 | ACTG1, TP53, PTPN11 | More | | Mafenide | hsa05211 | Renal cell carcinoma | 7.75E-03 | 2 | Q06124, Q99814 | PTPN11, EPAS1 | More | | Mafenide | hsa05212 | Pancreatic cancer | 2.60E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | | Mafenide | hsa05213 | Endometrial cancer | 2.60E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | | Mafenide | hsa05214 | Glioma | 2.60E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | | Mafenide | hsa05216 | Thyroid cancer | 1.14E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | | Mafenide | hsa05217 | Basal cell carcinoma | 2.06E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | | Mafenide | hsa05218 | Melanoma | 1.14E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | | Mafenide | hsa05220 | Chronic myeloid leukemia | 7.90E-03 | 3 | Q06124, P04637, P24522 | PTPN11, TP53, GADD45A | More | | Mafenide | hsa05223 | Non-small cell lung cancer | 3.19E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | | Mafenide | hsa05224 | Breast cancer | 4.51E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | | Mafenide | hsa05225 | Hepatocellular carcinoma | 3.30E-02 | 3 | P04637, P24522, P63261 | TP53, GADD45A, ACTG1 | More | | Mafenide | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.34E-02 | 5 | O95267, P20963, P09693, P06239, Q04759 | RASGRP1, CD247, CD3G, LCK, PRKCQ | More | | Mafenide | hsa05310 | Asthma | 2.35E-04 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Mafenide | hsa05321 | Inflammatory bowel disease | 1.03E-06 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | Mafenide | hsa05322 | Systemic lupus erythematosus | 3.06E-03 | 10 | O75015, P08246, P08311, P01375, P10747, P13765, Q6FI13, Q16778, P12814, P05455 | FCGR3B, ELA2, CTSG, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST2H2BE, ACTN1, SSB | More | | Mafenide | hsa05332 | Graft-versus-host disease | 3.02E-04 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Mafenide | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | |